Wrap Text
TR-1: Standard form for notification of major holdings
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company”, or the “Group”)
6 April 2023
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00B8HX8Z88
Issuer Name
MEDICLINIC INTERNATIONAL PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights; An acquisition or disposal of financial
instruments
3. Details of person subject to the notification obligation
Name
The Goldman Sachs Group, Inc.
City of registered office (if applicable)
Wilmington, Delaware
Country of registered office (if applicable)
USA
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the
notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
03-Apr-2023
6. Date on which Issuer notified
05-Apr-2023
7. Total positions of person(s) subject to the notification obligation
% of voting rights % of voting rights Total of both in Total number of
. attached to shares through financial % (8.A + 8.B) voting rights held
(total of 8.A) instruments (total of in issuer
8.B 1 + 8.B 2)
Resulting situation 0.010572 1.221842 1.232414 9085901
on the date on
which threshold
was crossed or
reached
Position of previous 1.074447 3.974818 5.049265
notification (if
applicable)
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares Number of direct Number of indirect % of direct voting % of indirect voting
ISIN code(if possible) voting rights voting rights (DTR5.2.1) rights (DTR5.1) rights (DTR5.2.1)
(DTR5.1)
GB00B8HX8Z88 77943 0.010572
Sub Total 8.A
77943 0.010572%
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial Expiration date Exercise/conversion Number of voting % of voting rights
instrument period rights that may be
acquired if the
instrument is
exercised/converted
Securities Open 9007921 1.221837
Lending
Sub Total 8.B1
9007921 1.221837%
8B2. Financial Instruments with similar economic effect according to
(DTR5.3.1R.(1) (b))
Type of Expiration date Exercise/conversion Physical or cash Number of voting % of voting
financial period settlement rights rights
instrument
Swap 30-May- Cash 37 0.000005
2023
Sub Total 8.B2
37 0.000005%
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling
natural person or legal entities (please add additional rows as necessary)
Ultimate controlling Name of controlled undertaking % of voting % of voting rights Total of both if it
person rights if it through financial equals or is
equals or is instruments if it equals higher than the
higher than or is higher than the notifiable
the notifiable notifiable threshold threshold
threshold
The Goldman
Sachs Group,
Inc. (Chain 1)
The Goldman Goldman Sachs (UK)
Sachs Group, L.L.C.
Inc. (Chain 1)
The Goldman Goldman Sachs
Sachs Group, Group UK Limited
Inc. (Chain 1)
The Goldman Goldman Sachs
Sachs Group, International
Inc. (Chain 1)
The Goldman
Sachs Group,
Inc. (Chain 2)
The Goldman GSAM Holdings LLC
Sachs Group,
Inc. (Chain 2)
The Goldman Goldman Sachs
Sachs Group, Asset Management,
Inc. (Chain 2) L.P.
The Goldman
Sachs Group,
Inc. (Chain 3)
The Goldman Goldman Sachs Bank
Sachs Group, USA
Inc. (Chain 3)
The Goldman Goldman Sachs Bank
Sachs Group, Europe SE
Inc. (Chain 3)
The Goldman
Sachs Group,
Inc. (Chain 4)
The Goldman Goldman Sachs &
Sachs Group, Co. LLC
Inc. (Chain 4)
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
Please note, positions previously reportable are now exempt under the market
making exemption as they are below the 10% limit.
Please note, the total amount of voting rights has been rounded to 6 decimal
places therefore there is a possibility of a rounding error.
General email contact:
gs-regops-emea-position-enquiries@gs.com
12. Date of Completion
05-Apr-2023
13. Place Of Completion
Warsaw
ABOUT MEDICLINIC INTERNATIONAL PLC
Mediclinic is a diversified international private healthcare services group, established in
South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and
Namibia) and the Middle East.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.
At 31 December 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, three
mental health facilities, 21 day case clinics and 23 outpatient clinics. The Swiss operations
included 17 hospitals and five day case clinics with around 1 900 inpatient beds; Southern
Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals,
three mental health facilities and 14 day case clinics (four of which operated by Intercare)
across South Africa, and around 8 750 inpatient beds; and the Middle East operated seven
hospitals, two day case clinics and 23 outpatient clinics with around 1000 inpatient beds in
the UAE. In addition, under management contract the Middle East will open a 200-bed
hospital in the Kingdom of Saudi Arabia in 2023.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United
Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock
Exchange in Namibia.
Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.
CONTACT INFORMATION
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
ir@mediclinic.com
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 06-04-2023 12:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
